Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World April 2, 2013 Bibiana Campos Seijo	More job cuts... The news came in that AstraZeneca is to invest 330 million pounds in a new strategic R&D center and global headquarters in Cambridge, UK. Unfortunately, there is also a negative angle to this story.
Chemistry World February 2, 2012 Andrew Turley	AstraZeneca to cut 7300 more jobs UK drugmaker AstraZeneca has announced plans to cut a further 7300 jobs to make annual savings of $1.6 billion by the end of 2014, a move that will cost the company $2.1 billion in the near term.
Chemistry World June 19, 2013 Laura Howes	AstraZeneca announce new UK hub The new hub will consolidate all of AZ's UK activities, including biologics arm MedImmune, at the Cambridge Biomedical Campus on the southern outskirts of the city.
Chemistry World January 18, 2012 Patrick Walter	Shell shutters UK R&D site The research currently carried out at the facility will be transferred to overseas sites. The announcement has fueled concerns in the UK research community that the country's opportunity to become a high-tech economy is slipping away.
Chemistry World January 30, 2014 Phillip Broadwith	AstraZeneca ends R&D in India Pharmaceutical firm AstraZeneca is quitting its R&D site in Bangalore, India.
Chemistry World January 28, 2010 Nina Notman	AstraZeneca's workforce slashed again Pharma giant AstraZeneca is to cut another 8,000 jobs globally over the next four years - with approximately 1,800 additional research and development staff to be lost.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
Chemistry World August 3, 2012 Andrew Turley	Pfizer secures Sandwich buyer Pfizer has found a buyer for its R&D site in Sandwich, UK: the site -- now called Discovery Park -- has been bought by a private consortium, according to Kent County Council.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
Chemistry World October 1, 2008 Victoria Gill	GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy.
Chemistry World March 20, 2008 Richard Van Noorden	UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market.
IndustryWeek January 1, 2004 John S. McClenahen	Expanding The Discovery Channel Additional R&D labs at AstraZeneca in Waltham, Mass., promise to aid in development of cancer and infectious disease drugs.
Chemistry World September 17, 2007	Uk Pharma Shifts Manufacturing Overseas Drug firm AstraZeneca has today reiterated that it will outsource drug manufacturing.
Chemistry World April 16, 2010 Sean Milmo	Ineos starts UK chemicals exodus Ineos's decision to relocate its headquarters to Switzerland because of corporate taxation concerns may spark an exodus of chemical and pharmaceutical companies from having their headquarters in the UK.
Chemistry World May 7, 2013 Phillip Broadwith	AstraZeneca site to become biotech hub The first three companies have already moved in, and more will hopefully follow to fill the space left by AZ as it relocates to Cambridge, UK.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.
Chemistry World January 28, 2013 Maria Burke	Plan for UK's 'eight great technologies' outlined Advanced materials and energy are two of the 'eight great technologies' that the UK government wants to use to propel the country to future growth.
Chemistry World March 22, 2012 Andrew Turley	GSK to build 350 million factory in UK GlaxoSmithKline has announced plans to build its first new UK production plant for almost 40 years in Ulverston, Cumbria.
Chemistry World September 18, 2012 Laura Howes	Battery boost for electric cars The UK government, in collaboration with industry, is to create a new UK energy storage R&D center to accelerate the development of batteries for vehicles.
Chemistry World March 2011 Bea Perks	Editorial: At the forefront The news that most of Pfizer's 2400 employees at Sandwich, U.K. will be made redundant over the next two years was met with surprise, disappointment and anger.
Pharmaceutical Executive December 1, 2011	UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity.
Chemistry World May 8, 2012 Helen Carmichael	Pharma firms see mixed fortunes in Quebec Quebec's life sciences and pharmaceutical industry has suffered several blows in 2012, with hundreds of R&D jobs being lost. This comes despite the industry receiving hundreds of millions of dollars in government assistance and favorable tax rates.
Chemistry World February 4, 2010 Matt Wilkinson	More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets.
The Motley Fool September 10, 2008 Brian Orelli	Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies.
Chemistry World April 3, 2014 Emma Stoye	Pharma giants plan new public--private collaborations AstraZeneca will partner with the Medical Research Council, in its new Cambridge site, while the Wellcome Trust Genome Campus will host a new center for target validation studies, jointly founded with the European Bioinformatics Institute and GlaxoSmithKline.
Chemistry World October 1, 2015 Phillip Broadwith	Human capital The wave of mergers and acquisitions -- particularly in the pharmaceutical sector, but also to some degree in fine and specialty chemicals -- highlights the growing importance of small and medium-sized enterprises in the business landscape.
Chemistry World June 24, 2011 Andrew Turley	Pfizer to Keep 350 Jobs at Sandwich US drug giant Pfizer has said that it will keep 350 jobs at its site in Sandwich, UK.
Chemistry World December 10, 2014	Big pharma opens up abandoned drugs Sixty eight stalled pharmaceutical compounds are being made available for academic research through the UK Medical Research Council.
Chemistry World November 6, 2013 Laura Howes	Novartis to shut Horsham site Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D.
Chemistry World May 6, 2014 Maria Burke	Public money for science pays off A new report claims to provide 'crucial economic evidence' to support claims that the UK government can boost growth by investing in science and engineering research.
Chemistry World September 23, 2010 Anna Lewcock	UK faces scientific exodus The UK faces a 'significant' risk of researchers abandoning its shores and long-term damage to the science base if proposed funding cuts go ahead
Chemistry World May 14, 2014 Andy Extance	Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca.
Chemistry World April 24, 2007 Victoria Gill	AstraZeneca Scoops up $15.6 Billion Vaccine Business AstraZeneca has joined the race to scoop up acquisition opportunities in the biologics sector with a $15.6 billion deal to buy U.S. vaccines and biotechnology company MedImmune.
Chemistry World October 25, 2013 Emily James	AstraZeneca to close environmental lab and cut 71 jobs The 71 employees at the Brixham Environmental Laboratory in Devon, UK. will lose their jobs in March 2014, as the laboratory's environmental operations are not a core part of the company's strategy to develop innovative new medicines.
Chemistry World November 9, 2015 Emma Stoye	UK science's 'superpower' status at risk The UK government must commit to spend more on science R&D in the long-term if the UK is to remain a 'scientific superpower', according to a report published by the House of Commons
Chemistry World February 18, 2010 Matt Wilkinson	Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut.
Chemistry World December 15, 2009 Sarah Houlton	Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu.
Bio-IT World October 14, 2004 Robinson & Violino	Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape.
Chemistry World April 9, 2009 Nina Notman	UK launches materials chemistry brokering service A multi-million pound center acting as a one-stop-shop for firms looking to contract out their materials chemistry research has officially opened in the north of England.
The Motley Fool May 15, 2006 Brian Gorman	AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note.
Chemistry World September 2009	Education and wealth It seems that the UK government is interested in answering the question: what return does the UK get for the money it puts into academic research in chemistry?
Chemistry World February 2, 2007 Victoria Gill	AstraZeneca Follows Pfizer in Slashing Workforce The Anglo-Swedish pharmaceutical hopes that by streamlining its operation it can offset the growing financial threat from cheap generic copies of its best-selling blood pressure drug. Nevertheless, the company has reported unexpectedly cheerful fourth quarter profits.
Chemistry World January 2012	Rising interest in compound bank David Fox argues for the creation of a centralized repository for small molecules to harness research efforts in drug discovery
Chemistry World February 20, 2013 Laura Howes	UK-India projects launched To coincide with the prime minister's visit to India, UK universities have announced a series of research partnerships and scholarships intended to boost the trade and education links between the UK and India.
Chemistry World December 4, 2014 Ageli Mehta	Cash for science in autumn statement given cautious welcome The UK chancellor, George Osborne, has told MPs that science is 'a personal priority' but the commitments in yesterday's autumn statement drew only a cautious welcome from science bodies.
The Motley Fool April 26, 2007 Brian Lawler	AstraZeneca's Announcement Overshadows Earnings AstraZeneca releases first-quarter financial results. Investors, take note.
Chemistry World November 25, 2010 Mike Brown	Capping scientific migrants A new UK immigration cap could bias against researchers looking to come to the UK.
Chemistry World September 2007 Ian Pearson	Comment: Global Science Matters The UK's new science minister says that an international perspective is vital for scientific growth.
Chemistry World March 9, 2010 Anna Lewcock	Fund science or risk economic downfall Leading researchers and former science ministers have today warned the UK government it risks 'throwing away' years of investment unless the UK keeps pace with science funding levels in other countries.
Chemistry World December 8, 2015 Jennifer Newton	Pfizer to close Cambridge pain outpost Pfizer plans to shut down its Neusentis site on the outskirts of Cambridge, UK, in a move that will eliminate up to 120 jobs.